GLP-1 Therapies Show Distinct Cardiometabolic Profiles

Key Takeaways

• In 19 randomized trials of adults with overweight or obesity, glucagon-like peptide-1 receptor agonists showed differing cardiometabolic profiles rather than a uniform class pattern.
• Higher-dose glucagon-like peptide-1 receptor agonists generally showed greater overall cardiometabolic improvement; the highest-ranked therapies also produced large placebo-adjusted weight reductions, ranging from approximately 10% to 15%.
• Compared with semaglutide 2.4 mg, orforglipron 36 mg contributed more strongly on glycemic control, HDL-C, and systolic blood pressure, whereas semaglutide 2.4 mg contributed more strongly on body weight, waist circumference, and LDL-C.
• Oral glucagon-like peptide-1 options were reported to remain competitive with injectable therapies in the comparative cardiometabolic rankings.

Adults with overweight or obesity often have cardiometabolic treatment goals that extend beyond weight loss alone, including glycemia, lipids, blood pressure, and central adiposity. Whether different glucagon-like peptide-1 (GLP-1) receptor agonists and doses align differently across those domains remains a practical question as use of these agents broadens, prompting investigators to examine the issue in a study.

In Ying Lu and colleagues’ GLP-1 cardiometabolic network meta-analysis, investigators conducted a systematic review and network meta-analysis of oral and subcutaneous GLP-1 receptor mono-agonists in adults with overweight or obesity. The analysis included 19 randomized controlled trials with 13,117 participants and used the Cardiometabolic Efficacy Index (CEI), a 0-to-1 ranking-based composite derived from SUCRA rankings across seven cardiometabolic endpoints. This framework extended the comparison beyond weight alone.

Injected semaglutide 7.2 mg had the highest reported CEI at 0.86, followed by orforglipron 36 mg at 0.68 and injected semaglutide 2.4 mg at 0.66. The top-ranked therapies also produced placebo-adjusted average weight reductions of at least 10% of body weight, placing the strongest overall composite signal among higher-dose options.

Across agents, higher-dose GLP-1 receptor agonists generally showed greater overall cardiometabolic improvement, and the investigators reported a dose-response relationship for semaglutide and orforglipron. Orforglipron appeared stronger for blood sugar control, HDL cholesterol, and systolic blood pressure, whereas semaglutide appeared stronger for body weight, waist circumference, and LDL cholesterol. In adults without type 2 diabetes, orforglipron 36 mg and oral semaglutide 25 mg had similar reported CEI values of 0.67 and 0.63, and in adults with type 2 diabetes, orforglipron ranked behind the higher-dose injected semaglutide option and ahead of the lower-dose semaglutide option. Oral options remained competitive within the network comparison.

The network included substantial heterogeneity and inconsistency for several outcomes, and the CEI is a ranking-based descriptive composite rather than a calibrated measure of clinical benefit.

Overall, GLP-1 receptor mono-agonists showed agent- and dose-specific differences across weight, glycemia, lipids, and blood pressure rather than a single class-wide profile. The investigators interpreted that pattern as supporting a more individualized cardiometabolic treatment framework rather than a prescribing rule.

Clinician Questions

What did the Cardiometabolic Efficacy Index include in the GLP-1 comparison?

The CEI combined body weight, waist circumference, hemoglobin A1c, systolic blood pressure, triglycerides, HDL cholesterol, and LDL cholesterol to summarize multidomain cardiometabolic effects in adults with overweight or obesity.

Which adults were represented in the GLP-1 cardiometabolic network meta-analysis?

The network meta-analysis synthesized randomized controlled trials in adults with overweight or obesity, and the reported subgroup findings included adults with and without type 2 diabetes.

How did the reported cardiometabolic strengths differ between semaglutide and orforglipron?

The reported pattern suggested complementary strengths rather than a single dominant profile, with orforglipron favoring blood sugar control, HDL cholesterol, and systolic blood pressure, and semaglutide favoring body weight, waist circumference, and LDL cholesterol.